Lucentis vs PDT: which is more cost-effective?

Article

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.

Please click here to read the abstract.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Related Content
Site Logo

Interactive vision simulator illustrates the vision loss caused by retinal diseases

April 23rd 2024
Article

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

Site Logo

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023
Podcast
A cell in amniotic fluid. Image credit: ©Icruci – stock.adobe.com

Amniotic membrane could move the needle outside of the operating room

April 19th 2024
Article

The tissue serves as a testing ground for outpatient ocular therapies

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022
Podcast
Lohith Shetty. Image courtesy of SCHWIND

SCHWIND appoints new head of global marketing solutions

April 17th 2024
Article

Lohith Shetty will lead marketing for the company, based in Kleinostheim, Germany

An elderly woman undergoes an eye exam. Image credit: ©cherryandbees – stock.adobe.com

I-SCREEN programme will use AI and OCT imaging to identify and monitor AMD

April 17th 2024
Article

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

© 2024 MJH Life Sciences

All rights reserved.